Aktis Oncology (NASDAQ:AKTS) & Valneva (NASDAQ:VALN) Financial Comparison

Valneva (NASDAQ:VALN) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Valneva and Aktis Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56 million	2.75	-$130.33 million	($2.11)	-2.71
Aktis Oncology	$6.50 million	134.04	-$63.73 million	($0.82)	-19.77

Aktis Oncology has lower revenue, but higher earnings than Valneva. Aktis Oncology is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Valneva and Aktis Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2	0	1	0	1.67
Aktis Oncology	1	0	9	1	2.91

Valneva presently has a consensus price target of $9.30, suggesting a potential upside of 62.87%. Aktis Oncology has a consensus price target of $35.62, suggesting a potential upside of 119.77%. Given Aktis Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Aktis Oncology is more favorable than Valneva.

Insider & Institutional Ownership

11.4% of Valneva shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Valneva and Aktis Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Valneva on 11 of the 14 factors compared between the two stocks.

About Valneva

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.